Summary
Abdominal aortic aneurysm (AAA) is a focal enlargement of the abdominal aorta below the renal arteries and is found in up to 4 million patients globally each year. If left untreated it can be fatal, so it is imperative to provide early, prophylactic treatment before a rupture occurs. The available treatment options are far from optimal: open surgery is a durable, life-long, but high-risk solution. The alternative, EVAR, has lower immediate risks, but is a shorter-term solution and requires continual monitoring and secondary interventions.
We have developed Aortoseal, a fixation and sealing implant for endovascular aneurysm repair that combines the best of both worlds: the stability of an open, sutured repair and the safety and low-risk delivery of EVAR. Aortoseal will reduce the need for open surgery, the need for secondary procedures and time in the hospital, all leading to improved patient outcomes and projected healthcare savings over a 10 year period of ~€9 bn across the EU.
We have developed Aortoseal, a fixation and sealing implant for endovascular aneurysm repair that combines the best of both worlds: the stability of an open, sutured repair and the safety and low-risk delivery of EVAR. Aortoseal will reduce the need for open surgery, the need for secondary procedures and time in the hospital, all leading to improved patient outcomes and projected healthcare savings over a 10 year period of ~€9 bn across the EU.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/190131747 |
| Start date: | 01-02-2023 |
| End date: | 31-01-2025 |
| Total budget - Public funding: | 6 480 638,35 Euro - 2 499 999,00 Euro |
Cordis data
Original description
Abdominal aortic aneurysm (AAA) is a focal enlargement of the abdominal aorta below the renal arteries and is found in up to 4 million patients globally each year. If left untreated it can be fatal, so it is imperative to provide early, prophylactic treatment before a rupture occurs. The available treatment options are far from optimal: open surgery is a durable, life-long, but high-risk solution. The alternative, EVAR, has lower immediate risks, but is a shorter-term solution and requires continual monitoring and secondary interventions.We have developed Aortoseal, a fixation and sealing implant for endovascular aneurysm repair that combines the best of both worlds: the stability of an open, sutured repair and the safety and low-risk delivery of EVAR. Aortoseal will reduce the need for open surgery, the need for secondary procedures and time in the hospital, all leading to improved patient outcomes and projected healthcare savings over a 10 year period of ~€9 bn across the EU.
Status
SIGNEDCall topic
HORIZON-EIC-2022-ACCELERATOROPEN-01Update Date
31-07-2023
Images
No images available.
Geographical location(s)
